Skip to main content
. Author manuscript; available in PMC: 2021 Oct 12.
Published in final edited form as: ACS Biomater Sci Eng. 2020 Sep 10;6(10):5941–5958. doi: 10.1021/acsbiomaterials.0c01075

Figure 11. ICOS expression was upregulated on splenic CD4+ T cells in ultra-low-dose aCD3 treated mice.

Figure 11.

Twelve-week-old pre-diabetic NOD mice received aCD3 and dMP treatment at identical time points as in the prevention study (Figure 4A) and were euthanized at 20 weeks of age, prior to the sixth dMP injection. As before, MP injections were administered subcutaneously on the right side of the abdomen and lymphoid organs excised and (A) stained for flow cytometry (n = 4–5/group). Positive expression of regulatory markers (B) PD-1 and (C) ICOS was characterized on splenic CD4+ T cells. P-values (* ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001) were obtained by one-way ANOVA with Tukey’s significance test. Data is represented by mean ± SEM. Full gating scheme – see Supplemental Figure 12.